Crinetics Pharmaceuticals (CRNX) Current Deferred Revenue (2022 - 2026)

Crinetics Pharmaceuticals' Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 80.5% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (down 80.5% YoY), while the FY2025 annual figure was $1.2 million, down 82.05% from the prior year.
• Current Deferred Revenue was $1.3 million for Q1 2026 at Crinetics Pharmaceuticals, up from $1.2 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $9.4 million in Q2 2022 to a low of $1.2 million in Q4 2025.
• Historically, Current Deferred Revenue has averaged $4.8 million across 5 years, with a median of $6.5 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue soared 185.88% in 2023, then slumped 82.05% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $8.3 million in 2022, then decreased by 18.4% to $6.8 million in 2023, then grew by 1.09% to $6.9 million in 2024, then plunged by 82.05% to $1.2 million in 2025, then increased by 2.91% to $1.3 million in 2026.
• The last three Current Deferred Revenue figures came in at $1.3 million (Q1 2026), $1.2 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.